These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35302171)

  • 21. LncRNA highly upregulated in liver cancer regulates imatinib resistance in chronic myeloid leukemia via the miR-150-5p/MCL1 axis.
    Han Y; Ma Z
    Anticancer Drugs; 2021 Apr; 32(4):427-436. PubMed ID: 33587348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homoharringtonine contributes to imatinib sensitivity by blocking the EphB4/RhoA pathway in chronic myeloid leukemia cell lines.
    Huang BT; Zeng QC; Zhao WH; Tan Y
    Med Oncol; 2014 Feb; 31(2):836. PubMed ID: 24415355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of
    Deng Y; Li X; Feng J; Zhang X
    Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
    Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
    Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS
    Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs.
    Stella S; Tirrò E; Conte E; Stagno F; Di Raimondo F; Manzella L; Vigneri P
    Mol Cancer Ther; 2013 Jun; 12(6):1085-98. PubMed ID: 23536723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wee1 promotes cell proliferation and imatinib resistance in chronic myeloid leukemia via regulating DNA damage repair dependent on ATM-γH2AX-MDC1.
    Zeng F; Peng Y; Qin Y; Wang J; Jiang G; Feng W; Yuan Y
    Cell Commun Signal; 2022 Dec; 20(1):199. PubMed ID: 36575478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
    Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia.
    Wen F; Cao YX; Luo ZY; Liao P; Lu ZW
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):1-8. PubMed ID: 30366670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein.
    Liao HC; Chou YJ; Lin CC; Liu SH; Oswita A; Huang YL; Wang YL; Syu JL; Sun CM; Leu CM; Lin CH; Fu SL
    Biochem Pharmacol; 2019 May; 163():308-320. PubMed ID: 30822403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adhesion to stromal cells mediates imatinib resistance in chronic myeloid leukemia through ERK and BMP signaling pathways.
    Kumar A; Bhattacharyya J; Jaganathan BG
    Sci Rep; 2017 Aug; 7(1):9535. PubMed ID: 28842696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J; Shen P; Zhang G; Wu X; Zhang X
    Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.
    Aranda-Tavío H; Recio C; Martín-Acosta P; Guerra-Rodríguez M; Brito-Casillas Y; Blanco R; Junco V; León J; Montero JC; Gandullo-Sánchez L; McNaughton-Smith G; Zapata JM; Pandiella A; Amesty A; Estévez-Braun A; Fernández-Pérez L; Guerra B
    Biomed Pharmacother; 2021 Dec; 144():112330. PubMed ID: 34673425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heme oxygenase-1 contributes to imatinib resistance by promoting autophagy in chronic myeloid leukemia through disrupting the mTOR signaling pathway.
    Cao L; Wang J; Ma D; Wang P; Zhang Y; Fang Q
    Biomed Pharmacother; 2016 Mar; 78():30-38. PubMed ID: 26898422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells.
    Li X; Pang J; Xue W; Wang Y; Tian T; Elgehama A; Wu X; Wu X; Sun Y; Qiu H; Shen Y; Xu Q
    Toxicol Appl Pharmacol; 2018 Dec; 360():249-256. PubMed ID: 30290167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia.
    Han SH; Korm S; Han YG; Choi SY; Kim SH; Chung HJ; Park K; Kim JY; Myung K; Lee JY; Kim H; Kim DW
    Autophagy; 2019 Dec; 15(12):2076-2090. PubMed ID: 30929559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells.
    Hirao T; Yamaguchi M; Kikuya M; Chibana H; Ito K; Aoki S
    Cancer Sci; 2018 Jan; 109(1):121-131. PubMed ID: 29121435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global identification of circular RNAs in imatinib (IM) resistance of chronic myeloid leukemia (CML) by modulating signaling pathways of circ_0080145/miR-203/ABL1 and circ 0051886/miR-637/ABL1.
    Lu YH; Huang ZY
    Mol Med; 2021 Nov; 27(1):148. PubMed ID: 34781898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
    Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY
    Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
    Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Wang X; Shi X; Liu J
    Cell Death Dis; 2017 Jul; 8(7):e2913. PubMed ID: 28682311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.